Related Experiment Videos

Effect of diaspirin cross-linked hemoglobin and norepinephrine on systemic hemodynamics and regional circulation in

A C Sharma1, A Gulati

  • 1Department of Pharmaceutics and Pharmacodynamics, University of Illinois, Chicago Health Sciences Center 60612-7231.

Insights

Diaspirin cross-linked hemoglobin (DCLHb) matched norepinephrine's (NE) pressor effect without reducing blood flow to organs. Unlike NE, DCLHb increased or maintained blood flow to vital organs, indicating a safer hemodynamic profile.

Area of Science:

  • Cardiovascular Physiology
  • Hemoglobin-based Oxygen Carriers
  • Pharmacology

Background:

  • Hemoglobin-based oxygen carriers (HBOCs) are investigated as blood substitutes.
  • Diaspirin cross-linked hemoglobin (DCLHb) is a modified HBOC.
  • Understanding the hemodynamic effects of DCLHb is crucial for its clinical application.

Purpose of the Study:

  • To compare the hemodynamic effects of diaspirin cross-linked hemoglobin (DCLHb) with norepinephrine (NE).
  • To evaluate the impact of DCLHb and NE on organ-specific blood flow and vascular resistance.
  • To assess the safety profile of DCLHb regarding circulatory function.

Main Methods:

  • Intravenous administration of DCLHb (400 mg/kg) and norepinephrine (NE) (25 micrograms/kg/min) in a preclinical model.
  • Measurement of systemic hemodynamic parameters: blood pressure, heart rate, cardiac output, and total peripheral resistance.
  • Assessment of regional blood flow and vascular resistance in various organs (heart, kidneys, brain, gastrointestinal tract, spleen, skin, musculo-skeletal system).

Main Results:

  • DCLHb and NE produced equivalent pressor effects.
  • DCLHb increased total peripheral resistance, while NE increased it more significantly.
  • DCLHb did not decrease blood flow to any organ; NE significantly reduced blood flow to several organs, including kidneys and spleen.

Conclusions:

  • DCLHb demonstrates a favorable hemodynamic profile compared to NE, maintaining organ perfusion.
  • DCLHb represents a potentially safer alternative to vasopressors like NE for managing blood pressure.
  • Further research into DCLHb's therapeutic potential in conditions requiring circulatory support is warranted.

Related Concept Videos